Skip to main content
. Author manuscript; available in PMC: 2022 Feb 18.
Published in final edited form as: JACC Cardiovasc Interv. 2021 Aug 23;14(16):1757–1767. doi: 10.1016/j.jcin.2021.06.036

Table 2.

Procedural medications in patients undergoing PCI with or without marijuana use, before and after propensity score matching.

Before matching
Reported marijuana use
No Yes P-value ASD (%)
 N (%) n= 109,507 (96.5%) n= 3,970 (3.5%)

Aspirin (any) 106711 (97.5) 3868 (97.5) 0.999 0.10%
Fondaparinux 88 (0.1) 4 (0.1) 0.873 0.70%
Direct Thrombin Inhibitor (other) 253 (0.2) 6 (0.2) 0.386 1.80%
Bivalirudin 39464 (36.0) 1359 (34.2) 0.021 3.80%
Unfractionated Heparin (any) 89546 (81.8) 3398 (85.6) <0.001 10.40%
Low Molecular Weight Heparins (any) 2907 (2.7) 114 (2.9) 0.432 1.30%
Glycoprotein IIb/IIIa inhibitor (any) 24713 (22.6) 1130 (28.5) <0.001 13.60%
Ticlopidine 99 (0.1) 1 (0.0) 0.277 2.70%
Prasugrel 15907 (14.5) 721 (18.2) <0.001 9.80%
Clopidogrel 65241 (59.6) 2104 (53.0) <0.001 13.30%
Ticagrelor 24965 (22.8) 1106 (27.9) <0.001 11.70%

After Matching
Reported marijuana use
No Yes P-value ASD (%)
 N (%) n= 3,803 (50.0%) n= 3,803 (50.0%)

Aspirin (any) 3705 (97.4) 3711 (97.6) 0.713 1.00%
Fondaparinux 3 (0.1) 4 (0.1) 1.000 0.90%
Direct Thrombin Inhibitor (other) 9 (0.2) 5 (0.1) 0.422 2.50%
Bivalirudin 1291 (33.9) 1299 (34.2) 0.866 0.40%
Unfractionated Heparin (any) 3276 (86.1) 3256 (85.6) 0.532 1.50%
Low Molecular Weight Heparins (any) 111 (2.9) 107 (2.8) 0.837 0.60%
Glycoprotein IIb/IIIa inhibitor (any) 1058 (27.8) 1064 (28.0) 0.898 0.40%
Ticlopidine 2 (0.1) 1 (0.0) 1.000 1.30%
Prasugrel 654 (17.2) 685 (18.0) 0.366 2.10%
Clopidogrel 2066 (54.3) 2035 (53.5) 0.490 1.60%
Ticagrelor 1081 (28.4) 1058 (27.8) 0.575 1.30%

Procedural medications are defined as medications administered between 24 hours prior to and during the procedure. Abbreviations: ASD = absolute standardized difference.

HHS Vulnerability Disclosure